Laura Calabresi

List of Publications by Citations

174 papers	6,156 citations	44 h-index	71 g-index
182 ext. papers	6,910 ext. citations	5.4 avg, IF	5.39 L-index

#	Paper	IF	Citations
174	Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. *Circulation*, **2001**, 103, 1949-54	16.7	287
173	Endothelial protection by high-density lipoproteins: from bench to bedside. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2003**, 23, 1724-31	9.4	193
172	Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. *Journal of Biological Chemistry*, **2002**, 277, 4301-8	5.4	179
171	Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1995**, 15, 1819-28	9.4	147
170	Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. *Biochemical and Biophysical Research Communications*, **1997**, 238, 61-5	3.4	140
169	The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 1972-8	9.4	136
168	Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. *Journal of Lipid Research*, **2007**, 48, 592-9	6.3	135
167	High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. *Circulation Research*, **2003**, 92, 330-7	15.7	133
166	Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. *Cell Metabolism*, **2010**, 12, 187-93	24.6	132
165	Structure of HDL: particle subclasses and molecular components. *Handbook of Experimental Pharmacology*, **2015**, 224, 3-51	3.2	130
164	Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. *Annals of Neurology*, **1995**, 37, 596-604	9.4	130
163	HDL and cholesterol handling in the brain. *Cardiovascular Research*, **2014**, 103, 405-13	9.9	116
162	Structure, function and amyloidogenic propensity of apolipoprotein A-I. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2006**, 13, 191-205	2.7	111
161	Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. *Biochemistry*, **2009**, 48, 11067-74	3.2	106
160	An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. *Metabolism: Clinical and Experimental*, **2004**, 53, 153-8	12.7	106
159	Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1999**, 19, 1257-62	9.4	106
158	Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. *Journal of Biological Chemistry*, **2004**, 279, 9930-6	5.4	103

157	Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2002**, 22, 656-61	9.4	98
156	Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations of ANGPTL3. *Circulation: Cardiovascular Genetics*, **2012**, 5, 42-50		89
155	Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses. *Atherosclerosis*, **2000**, 148, 387-96	3.1	88
154	Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease. *Atherosclerosis*, **2012**, 222, 299-306	3.1	87
153	Functional Lecithin: Cholesterol Acyltransferase Is Not Required for Efficient Atheroprotection in Humans. *Circulation*, **2009**, 1	16.7	82
152	Apolipoprotein A-I conformation in discoidal particles: evidence for alternate structures. *Biochemistry*, **1993**, 32, 6477-84	3.2	78
151	Lecithin:cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans. *Trends in Cardiovascular Medicine*, **2010**, 20, 50-3	6.9	66
150	Hypocholesterolaemic effects of lupin protein and pea protein/fibre combinations in moderately hypercholesterolaemic individuals. *British Journal of Nutrition*, **2012**, 107, 1176-83	3.6	64
149	Omega-3 fatty acid ethyl esters increase heart rate variability in patients with coronary disease. *Pharmacological Research*, **2002**, 45, 475	10.2	64
148	Functional LCAT is not required for macrophage cholesterol efflux to human serum. *Atherosclerosis*, **2009**, 204, 141-6	3.1	62
147	Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus. *Journal of Clinical Lipidology*, **2014**, 8, 61-8	4.9	61
146	A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux. *Journal of Biological Chemistry*, **2007**, 282, 5125-32	5.4	59
145	Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. *Gastroenterology*, **2004**, 126, 1416-22	13.3	59
144	Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. *Pharmacological Research*, **2007**, 55, 310-7	10.2	58
143	Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. *Atherosclerosis*, **2007**, 195, 385-91	3.1	58
142	Reconstituted high-density lipoproteins with a disulfide-linked apolipoprotein A-I dimer: evidence for restricted particle size heterogeneity. *Biochemistry*, **1997**, 36, 12428-33	3.2	56
141	Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. *Atherosclerosis*, **1998**, 139, 77-82	3.1	56
140	Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 74-80	9.4	53

139	Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer. *Biochemistry*, **1999**, 38, 16307-14	3.2	53
138	Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 324, 776-83	4.7	51
137	Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. *Circulation*, **2009**, 120, 628-35	16.7	48
136	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 50-67	18.1	48
135	High density lipoprotein and coronary heart disease: insights from mutations leading to low high density lipoprotein. *Current Opinion in Lipidology*, **1997**, 8, 219-24	4.4	46
134	The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential. *Journal of Lipid Research*, **2008**, 49, 954-60	6.3	46
133	Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2002**, 22, 1475-81	9.4	46
132	Synthetic high-density lipoproteins exert cardioprotective effects in myocardial ischemia/reperfusion injury. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 308, 79-84	4.7	45
131	Recombinant apolipoproteins for the treatment of vascular diseases. *Atherosclerosis*, **1999**, 142, 29-40	3.1	45
130	Acquired lecithin:cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease. *Journal of Internal Medicine*, **2015**, 277, 552-61	10.8	44
129	Activation of lecithin cholesterol acyltransferase by a disulfide-linked apolipoprotein A-I dimer. *Biochemical and Biophysical Research Communications*, **1997**, 232, 345-9	3.4	43
128	Lipoprotein X Causes Renal Disease in LCAT Deficiency. *PLoS ONE*, **2016**, 11, e0150083	3.7	43
127	HDL and atherosclerosis: Insights from inherited HDL disorders. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2015**, 1851, 13-8	5	42
126	Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases. *Current Atherosclerosis Reports*, **2006**, 8, 163-7	6	42
125	Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk. *Journal of Lipid Research*, **2011**, 52, 1569-74	6.3	41
124	Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy. *Advances in Therapy*, **2017**, 34, 1200-1210	4.1	39
123	Role of LCAT in Atherosclerosis. *Journal of Atherosclerosis and Thrombosis*, **2016**, 23, 119-27	4	39
122	Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome. *Cardiovascular Research*, **2013**, 100, 36-43	9.9	39

121	Apolipoprotein AIMilano. Partial lecithin:cholesterol acyltransferase deficiency due to low levels of a functional enzyme. *Lipids and Lipid Metabolism*, **1990**, 1043, 1-6		39
120	Normal vascular function despite low levels of high-density lipoprotein cholesterol in carriers of the apolipoprotein A-I(Milano) mutant. *Circulation*, **2007**, 116, 2165-72	16.7	38
119	Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux. *Journal of Lipid Research*, **2003**, 44, 539-46	6.3	38
118	Complete and Partial Lecithin:Cholesterol Acyltransferase Deficiency Is Differentially Associated With Atherosclerosis. *Circulation*, **2018**, 138, 1000-1007	16.7	35
117	Effect of soy on metabolic syndrome and cardiovascular risk factors: a randomized controlled trial. *European Journal of Nutrition*, **2018**, 57, 499-511	5.2	33
116	Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. *Pharmacological Research*, **2004**, 49, 493-9	10.2	33
115	Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini. *Biochemical Journal*, **2002**, 362, 627-634	3.8	32
114	The Extent of Human Apolipoprotein A-I Lipidation Strongly Affects the Amyloid Efflux Across the Blood-Brain Barrier. *Frontiers in Neuroscience*, **2019**, 13, 419	5.1	31
113	Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. *Journal of Clinical Lipidology*, **2013**, 7, 414-22	4.9	31
112	High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2005**, 1736, 136-43	5	31
111	High-Density Lipoprotein, Lecithin: Cholesterol Acyltransferase, and Atherosclerosis. *Endocrinology and Metabolism*, **2016**, 31, 223-9	3.5	31
110	Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes. *Journal of the American College of Cardiology*, **2018**, 71, 279-288	15.1	30
109	Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin. *Nutrition, Metabolism and Cardiovascular Diseases*, **2005**, 15, 47-55	4.5	30
108	Drug control of reverse cholesterol transport **1994**, 61, 289-324		30
107	eNOS activation by HDL is impaired in genetic CETP deficiency. *PLoS ONE*, **2014**, 9, e95925	3.7	30
106	Limited proteolysis of a disulfide-linked apoA-I dimer in reconstituted HDL. *Journal of Lipid Research*, **2001**, 42, 935-942	6.3	30
105	Recurrent mutations of the apolipoprotein A-I gene in three kindreds with severe HDL deficiency. *Atherosclerosis*, **2003**, 167, 335-45	3.1	29
104	A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred. *Atherosclerosis*, **2009**, 205, 506-11	3.1	28

103	High-density lipoprotein quantity or quality for cardiovascular prevention?. *Current Pharmaceutical Design*, **2010**, 16, 1494-503	3.3	28
102	Changes in high-density lipoprotein subfraction distribution and increased cholesteryl ester transfer after probucol. *American Journal of Cardiology*, **1988**, 62, 73B-76B	3	28
101	Abnormal splicing of ABCA1 pre-mRNA in Tangier disease due to a IVS2 +5G>C mutation in ABCA1 gene. *Journal of Lipid Research*, **2003**, 44, 254-64	6.3	27
100	Increased carotid artery intima-media thickness in subjects with primary hypoalphalipoproteinemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2002**, 22, 317-22	9.4	27
99	Plasma cholesterol homeostasis, HDL remodeling and function during the acute phase reaction. *Journal of Lipid Research*, **2017**, 58, 2051-2060	6.3	26
98	Recombinant human LCAT normalizes plasma lipoprotein profile in LCAT deficiency. *Biologicals*, **2013**, 41, 446-9	1.8	25
97	Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys. *Journal of Lipid Research*, **2013**, 54, 2341-53	6.3	25
96	Recombinant LCAT (Lecithin:Cholesterol Acyltransferase) Rescues Defective HDL (High-Density Lipoprotein)-Mediated Endothelial Protection in Acute Coronary Syndrome. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 915-924	9.4	24
95	Novel mutations of CETP gene in Italian subjects with hyperalphalipoproteinemia. *Atherosclerosis*, **2009**, 204, 202-7	3.1	24
94	The C-terminal domain of apolipoprotein A-I is involved in ABCA1-driven phospholipid and cholesterol efflux. *Biochemical and Biophysical Research Communications*, **2002**, 299, 801-5	3.4	24
93	Nutraceutical approach for the management of cardiovascular risk - a combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract: results from a randomized, double-blind, placebo-controlled study. *Nutrition Journal*, **2019**, 18, 13	4.3	23
92	Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano/POPC) in healthy volunteers and stable coronary artery disease patients. *Atherosclerosis*, **2016**, 255, 17-24	3.1	23
91	Omega-3 fatty acids selectively raise high-density lipoprotein 2 levels in healthy volunteers. *Metabolism: Clinical and Experimental*, **1991**, 40, 1283-6	12.7	23
90	Lupin protein exerts cholesterol-lowering effects targeting PCSK9: From clinical evidences to elucidation of the in vitro molecular mechanism using HepG2 cells. *Journal of Functional Foods*, **2016**, 23, 230-240	5.1	23
89	Apheretic treatment of severe familial hypercholesterolemia: comparison of dextran sulfate cellulose and double membrane filtration methods for low density lipoprotein removal. *Atherosclerosis*, **1988**, 73, 197-202	3.1	22
88	Lecithin:Cholesterol Acyltransferase Activation by Sulfhydryl-Reactive Small Molecules: Role of Cysteine-31. *Journal of Pharmacology and Experimental Therapeutics*, **2017**, 362, 306-318	4.7	21
87	Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini. *Biochemical Journal*, **2002**, 362, 627-34	3.8	21
86	Genetic, biochemical, and clinical features of LCAT deficiency: update for 2020. *Current Opinion in Lipidology*, **2020**, 31, 232-237	4.4	21

85	Hepatic ACAT2 knock down increases ABCA1 and modifies HDL metabolism in mice. *PLoS ONE*, **2014**, 9, e93552	3.7	20
84	Apolipoprotein A-II modulates HDL remodeling in plasma. *Lipids and Lipid Metabolism*, **1992**, 1124, 195-8		19
83	High Density Lipoproteins Inhibit Oxidative Stress-Induced Prostate Cancer Cell Proliferation. *Scientific Reports*, **2018**, 8, 2236	4.9	18
82	Nutraceutical approaches to metabolic syndrome. *Annals of Medicine*, **2017**, 49, 678-697	1.5	18
81	Apolipoprotein A-I breakdown is induced by thrombolysis in coronary patients. *Annals of Medicine*, **2007**, 39, 306-11	1.5	18
80	Tolerability of fibric acids. Comparative data and biochemical bases. *Pharmacological Research*, **1992**, 26, 243-60	10.2	18
79	Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention. *Journal of Clinical Lipidology*, **2015**, 9, 226-33	4.9	17
78	Apolipoprotein E epsilon 4 allele in Alzheimer's disease and vascular dementia. *Dementia and Geriatric Cognitive Disorders*, **1994**, 5, 240-2	2.6	17
77	Effects of established hypolipidemic drugs on HDL concentration, subclass distribution, and function. *Handbook of Experimental Pharmacology*, **2015**, 224, 593-615	3.2	17
76	Synthetic high density lipoproteins for the treatment of myocardial ischemia/reperfusion injury **2006**, 111, 836-54		16
75	Dysfunctional HDL as a Therapeutic Target for Atherosclerosis Prevention. *Current Medicinal Chemistry*, **2019**, 26, 1610-1630	4.3	16
74	Protective Effects of HDL Against Ischemia/Reperfusion Injury. *Frontiers in Pharmacology*, **2016**, 7, 2	5.6	16
73	Conformation of dimeric apolipoprotein A-I milano on recombinant lipoprotein particles. *Biochemistry*, **2010**, 49, 5213-24	3.2	15
72	Combined monogenic hypercholesterolemia and hypoalphalipoproteinemia caused by mutations in LDL-R and LCAT genes. *Atherosclerosis*, **2005**, 182, 153-9	3.1	15
71	Cholesterol trafficking-related serum lipoprotein functions in children with cholesteryl ester storage disease. *Atherosclerosis*, **2015**, 242, 443-9	3.1	14
70	Beta2-adrenergic activity modulates vascular tone regulation in lecithin:cholesterol acyltransferase knockout mice. *Vascular Pharmacology*, **2015**, 74, 114-121	5.9	14
69	Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations. *Clinica Chimica Acta*, **2011**, 412, 1262-5	6.2	14
68	The plasma concentration of Lpa-I:A-II particles as a predictor of the inflammatory response in patients with ST-elevation myocardial infarction. *Atherosclerosis*, **2009**, 202, 304-11	3.1	14

67	Inhibition of MMP-2 activation and release as a novel mechanism for HDL-induced cardioprotection. *FEBS Letters*, **2006**, 580, 5974-8	3.8	14
66	Comparison of the lipoprotein and hemostatic changes after a triphasic and a monophasic low dose oral contraceptive in premenopausal middle-aged women. *Atherosclerosis*, **1990**, 84, 203-11	3.1	14
65	Effects of a lupin protein concentrate on lipids, blood pressure and insulin resistance in moderately dyslipidaemic patients: A randomised controlled trial. *Journal of Functional Foods*, **2017**, 37, 8-15	5.1	13
64	A proteomic portrait of atherosclerosis. *Journal of Proteomics*, **2013**, 82, 92-112	3.9	12
63	Structure and function of the apoA-IV T347S and Q360H common variants. *Biochemical and Biophysical Research Communications*, **2010**, 393, 126-30	3.4	12
62	Severe high-density lipoprotein deficiency associated with autoantibodies against lecithin:cholesterol acyltransferase in non-Hodgkin lymphoma. *Archives of Internal Medicine*, **2012**, 172, 179-81		12
61	Denaturation and self-association of apolipoprotein A-I investigated by electrophoretic techniques. *Biochemistry*, **1997**, 36, 7898-905	3.2	12
60	A model structure for the heterodimer apoA-IMilano-apoA-II supports its peculiar susceptibility to proteolysis. *Biophysical Journal*, **2006**, 91, 3043-9	2.9	12
59	Cardiovascular risk changes after lipid lowering medications: are they predictable?. *Atherosclerosis*, **2000**, 152, 1-8	3.1	12
58	Alterations in the HDL system after rapid plasma cholesterol reduction by LDL-apheresis. *Metabolism: Clinical and Experimental*, **1988**, 37, 752-7	12.7	12
57	Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels. *Journal of Clinical Lipidology*, **2019**, 13, 778-787.e6	4.9	11
56	Size is a major determinant of dissociation and denaturation behaviour of reconstituted high-density lipoproteins. *Biochemical Journal*, **2002**, 366, 245-53	3.8	11
55	Depletion in LpA-I:A-II particles enhances HDL-mediated endothelial protection in familial LCAT deficiency. *Journal of Lipid Research*, **2017**, 58, 994-1001	6.3	10
54	Hypocomplementemic type II membranoproliferative glomerulonephritis in a male patient with familial lecithin-cholesterol acyltransferase deficiency due to two different allelic mutations. *Nephron*, **2001**, 88, 268-72	3.3	10
53	Progression of chronic kidney disease in familial LCAT deficiency: a follow-up of the Italian cohort. *Journal of Lipid Research*, **2020**, 61, 1784-1788	6.3	10
52	Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney Disease. *Journal of Clinical Medicine*, **2020**, 9,	5.1	10
51	Plasma-derived and synthetic high-density lipoprotein inhibit tissue factor in endothelial cells and monocytes. *Biochemical Journal*, **2016**, 473, 211-9	3.8	9
50	A novel mutation of the apolipoprotein A-I gene in a family with familial combined hyperlipidemia. *Atherosclerosis*, **2008**, 198, 145-51	3.1	9

49	High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease. *Expert Opinion on Therapeutic Targets*, **2006**, 10, 561-72	6.4	9
48	Molecular characterization of two patients with severe LCAT deficiency. *Nephrology Dialysis Transplantation*, **2007**, 22, 2379-82	4.3	9
47	A 33-year-old man with nephrotic syndrome and lecithin-cholesterol acyltransferase (LCAT) deficiency. Description of two new mutations in the LCAT gene. *Nephrology Dialysis Transplantation* , **2004**, 19, 1622-4	4.3	9
46	Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2018**, 1863, 991-997	5	9
45	Virtual genetic diagnosis for familial hypercholesterolemia powered by machine learning. *European Journal of Preventive Cardiology*, **2020**, 27, 1639-1646	3.9	8
44	Off-target effects of thrombolytic drugs: apolipoprotein A-I proteolysis by alteplase and tenecteplase. *Biochemical Pharmacology*, **2013**, 85, 525-30	6	8
43	Native LDL-induced oxidative stress in human proximal tubular cells: multiple players involved. *Journal of Cellular and Molecular Medicine*, **2011**, 15, 375-95	5.6	8
42	Structural features and dynamics properties of human apolipoprotein A-I in a model of synthetic HDL. *Journal of Molecular Graphics and Modelling*, **2009**, 28, 305-12	2.8	8
41	Human apolipoprotein A-II inhibits the formation of pre-beta high density lipoproteins. *Lipids and Lipid Metabolism*, **1996**, 1304, 32-42		8
40	LCAT deficiency: molecular and phenotypic characterization of an Italian family. *Journal of Nephrology*, **2006**, 19, 375-81	4.8	8
39	Lipoprotein glomerulopathy associated with a mutation in apolipoprotein e. *Clinical Medicine Insights: Case Reports*, **2013**, 6, 189-96	0.8	7
38	Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome. *Vascular Pharmacology*, **2015**, 74, 80-86	5.9	6
37	A complex phenotype in a child with familial HDL deficiency due to a novel frameshift mutation in APOA1 gene (apoA-IGuastalla). *Journal of Clinical Lipidology*, **2015**, 9, 837-846	4.9	6
36	Paradoxical decrease in high-density lipoprotein cholesterol with fenofibrate: a quite rare phenomenon indeed. *Cardiovascular Therapeutics*, **2010**, 28, 153-60	3.3	6
35	Lipid and apoprotein composition of HDL in partial or complete CETP deficiency. *Current Vascular Pharmacology*, **2012**, 10, 422-31	3.3	6
34	Structural and dynamic features of apolipoprotein A-I cysteine mutants, Milano and Paris, in synthetic HDL. *Journal of Molecular Graphics and Modelling*, **2010**, 29, 406-14	2.8	6
33	Japan: are statins still good for everybody?. *Lancet, The*, **2006**, 368, 1135-6	40	6
32	Distant homology modeling of LCAT and its validation through in silico targeting and in vitro and in vivo assays. *PLoS ONE*, **2014**, 9, e95044	3.7	6

31	Activation of Naturally Occurring Lecithin:Cholesterol Acyltransferase Mutants by a Novel Activator Compound. *Journal of Pharmacology and Experimental Therapeutics*, **2020**, 375, 463-468	4.7	6
30	Novel missense variants in LCAT and APOB genes in an Italian kindred with familial lecithin:cholesterol acyltransferase deficiency and hypobetalipoproteinemia. *Journal of Clinical Lipidology*, **2012**, 6, 244-50	4.9	5
29	LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters. *Atherosclerosis*, **2020**, 297, 8-15	3.1	4
28	Familial LCAT deficiency: from pathology to enzyme replacement therapy. *Clinical Lipidology*, **2015**, 10, 405-413		4
27	A woman with low HDL cholesterol and corneal opacity. *Internal and Emergency Medicine*, **2012**, 7, 533-7	3.7	4
26	HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD). *Biomedicines*, **2020**, 8,	4.8	4
25	A proteomic approach to identify novel disease biomarkers in LCAT deficiency. *Journal of Proteomics*, **2019**, 198, 113-118	3.9	4
24	Interactions of Oxysterols with Atherosclerosis Biomarkers in Subjects with Moderate Hypercholesterolemia and Effects of a Nutraceutical Combination (BB536, Red Yeast Rice Extract) (Randomized, Double-Blind, Placebo-Controlled Study). *Nutrients*, **2021**, 13,	6.7	4
23	Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A case-control study. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2015**, 22, 187-93	2.7	3
22	HDL and endothelial protection: examining evidence from HDL inherited disorders. *Clinical Lipidology*, **2013**, 8, 361-370		3
21	ApoA-IMilano from structure to clinical application. *Annals of Medicine*, **2008**, 40, 48-56	1.5	3
20	CETP levels rather than polymorphisms as markers of coronary risk: healthy athlete with high HDL-C and coronary disease--effectiveness of probucol. *Atherosclerosis*, **2006**, 186, 225-7	3.1	3
19	CER-001 ameliorates lipid profile and kidney disease in a mouse model of familial LCAT deficiency. *Metabolism: Clinical and Experimental*, **2021**, 116, 154464	12.7	3
18	Evidence-based medicine criteria applied to hypolipidemic and antihypertensive drug trials: is drug efficacy always the same?. *Pharmacological Research*, **1998**, 37, 339-43	10.2	2
17	LCAT deficiency: molecular genetics, lipid/lipoprotein phenotype and atherosclerosis. *Future Lipidology*, **2006**, 1, 241-245		2
16	The HDL mimetic CER-001 remodels plasma lipoproteins and reduces kidney lipid deposits in inherited lecithin:cholesterol acyltransferase deficiency. *Journal of Internal Medicine*, **2021**,	10.8	2
15	High-Density Lipoproteins and the Kidney. *Cells*, **2021**, 10,	7.9	2
14	rHDL modeling and the anchoring mechanism of LCAT activation. *Journal of Lipid Research*, **2020**, 62, 100006	6.3	2

List of Publications

13	Lecithin:Cholesterol Acyltransferase (LCAT) Deficiency: Molecular Genetics **2014**,		1
12	Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders.. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2022**, 1867, 159123	5	1
11	Genetic determinants of HDL metabolism. *Current Medicinal Chemistry*, **2014**, 21, 2855-63	4.3	1
10	Vasculoprotective properties of plasma lipoproteins from brown bears (Ursus arctos). *Journal of Lipid Research*, **2021**, 62, 100065	6.3	1
9	Genetic LCAT Deficiency: Molecular Diagnosis, Plasma Lipids, and Atherosclerosis **2010**, 89-93		1
8	Endothelial Protection by High-Density Lipoproteins375-398		0
7	Abdominal obesity negatively influences key metrics of reverse cholesterol transport. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2021**, 1867, 159087	5	0
6	HDL, Reverse Cholesterol Transport, and Atherosclerosis **2011**, 159-165		
5	Raising HDL cholesterol for cardiovascular disease prevention: Is this still feasible?. *Current Cardiovascular Risk Reports*, **2008**, 2, 35-40	0.9	
4	The Low-HDL Syndrome: Epidemiology and Pathophysiology. *Medical Science Symposia Series*, **2002**, 103-108		
3	Sex-Related Differences in the Phenotypic Expression of the Apolipoprotein A-IMilano Mutant **1993** , 267-277		
2	Intracoronary monocyte expression pattern and HDL subfractions after non-ST elevation myocardial infarction. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2021**, 1867, 166116	6.9	
1	Plasma fatty acid composition in familial LCAT deficiency indicates SOAT2-derived cholesteryl ester formation in humans. *Journal of Lipid Research*, **2022**, 100232	6.3	